$2.94
-0.07-2.33%
At close: Nov 13, 4:00 PM EST
Molecular Partners AG
MOLNNASDAQ
Molecular Partners fell 31.5% from $4.29 to $2.94, behind the S&P 500's +12.3%. Its worst day was Mar 13 (−14.7%), and its low came Nov 13 at $2.94.
Nov 14, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Molecular Partners shares rose 15.2%, while the S&P 500 rose 0.9%.
+15.2%, the year's best day · S&P 500 +0.9%
Molecular Partners closed at its highest level of the year, 23.5% above where the year started.
Story events cover the past 12 months · Times ET
+1.1% · S&P 500 −0.9%
EPS of $-0.41 missed the $-0.38 estimate on $0.00 revenue.
−14.7%, the year's worst day · S&P 500 −0.6%
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic windowMP0712, Radio-DARPin
+11.3% · S&P 500 −0.2%
EPS of $-0.45 missed the $-0.38 estimate on $0.00 revenue.
−5.8% · S&P 500 +0.6%
Molecular Partners shares rose 9.5%, while the S&P 500 rose 0.4%.
+9.5% · S&P 500 +0.4%
EPS of $-0.89 missed the $-0.45 estimate on $0.00 revenue.
−2.8% · S&P 500 +0.3%
EPS of $-0.38 beat the $-0.46 estimate on $0.00 revenue.
−1.9% · S&P 500 −0.4%
Where it ended: a close of $2.94 on Nov 13, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.44).
Nothing in the past 12 months.
All MOLN dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MOLN and SPY from Benzinga historical bars. Not investment advice.
